Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
Glaukos Corp chairman and CEO Thomas William Burns reported updated holdings of the company’s common stock, mainly through several family and charitable trusts. The filing lists indirect positions including 100,000 shares through the Janet M. Burns Irrevocable Trust and 1,141,593 shares through the Burns Family Trust.
The only actual share movement was a tax-withholding disposition of 4,059 directly held shares at $142.57 per share to satisfy tax obligations upon vesting and delivery of restricted stock units granted on March 18, 2021. After this, he directly holds 68,967 shares, and his position also includes 56,382 restricted stock units that have not yet vested or been delivered.
GLAUKOS Corp President & COO Joseph E. Gilliam reported a routine tax-related share disposition. On the vesting and delivery of previously granted restricted stock units, the company withheld 1,056 shares of common stock to cover his tax withholding obligations at $142.57 per share.
After this withholding, Gilliam directly holds 72,363 shares of common stock. This position includes 41,983 restricted stock units that have been granted but have not yet vested or been delivered, reflecting ongoing equity-based compensation rather than an open-market sale.
GLAUKOS Corp Chief Development Officer Tomas Navratil reported a small share disposition related to tax withholding, not a market sale. On this Form 4, 483 shares of common stock were withheld by the company at $142.57 per share to satisfy tax obligations upon vesting of restricted stock units granted on March 18, 2021.
After this tax-withholding event, Navratil directly holds 88,350 shares of GLAUKOS common stock, which the filing notes include 38,817 restricted stock units that have not yet vested or been delivered. This filing reflects a routine compensation and tax event rather than an open-market trade.
Glaukos Corp director Mark J. Foley reported a grant of 2,987 stock options for common stock, each with an exercise price of $106.52. These options were granted under the company’s Director Compensation Policy and vest in full on the one-year anniversary of the May 28, 2026 grant date.
This Form 4/A corrects an earlier filing that mistakenly listed the exercise price as $53.57. After this grant, Foley holds 2,987 stock options from this award, which are scheduled to expire on May 28, 2036 if not exercised.
Glaukos Corp director Leana Wen received a grant of stock options, and the amended Form 4 corrects their exercise price. On May 28, 2026 she was granted options for 2,987 shares of common stock at an exercise price of $106.52 per share, expiring on May 28, 2036. These options were granted under the company’s Director Compensation Policy and vest in full on the one-year anniversary of the grant date. After this grant, she holds 2,987 stock options directly.
GLAUKOS Corp director Marc Stapley reported a grant of stock options for 2,987 shares of Common Stock. These options carry an exercise price of $106.52 per share and were granted on May 28, 2026 under the issuer's Director Compensation Policy.
The options vest in full on the one-year anniversary of the grant date and expire on May 28, 2036. This Form 4/A also corrects a prior filing that had mistakenly reported the exercise price as $53.57, confirming the correct price as $106.52.
Glaukos Corp director Aimee S. Weisner received a grant of 2,987 stock options as director compensation. The options have an exercise price of $106.52 per share, were granted on May 28, 2026, and vest in full on the one-year anniversary of the grant date. They are scheduled to expire on May 28, 2036. This amended Form 4 corrects an earlier filing that had reported the exercise price incorrectly, and reflects a routine equity award rather than an open-market stock purchase or sale.
GLAUKOS Corp director Gilbert H. Kliman received a grant of 2,987 stock options, each with an exercise price of $106.52. The options relate to common stock and were awarded under the company’s Director Compensation Policy as part of his board compensation.
This Form 4/A is an amendment to a prior filing that had mistakenly reported the exercise price as $53.57. The options were granted on May 28, 2026, vest in full on the one-year anniversary of the grant date, and expire on May 28, 2036.
GLAUKOS Corp director David F. Hoffmeister received a grant of 2,987 stock options, and the company corrected the reported exercise price. The amended Form 4 updates a prior filing that mistakenly listed the strike price as $53.57; the correct exercise price is $106.52. These options, granted under the issuer’s Director Compensation Policy, vest in full on the one-year anniversary of the May 28, 2026 grant date and are exercisable until May 28, 2036, giving him the right to buy an equal number of common shares at that price.
GLAUKOS Corp director Denice Torres reported a stock option grant and corrected prior disclosure details. She received options for 2,987 shares of common stock at an exercise price of $106.52 per share, granted under the issuer's Director Compensation Policy. The options vest in full on the one-year anniversary of the May 28, 2026 grant date and expire on May 28, 2036. This Form 4/A also amends a prior Form 4 that mistakenly reported the exercise price as $53.57, clarifying that the correct exercise price is $106.52.